3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
1
Lymphoma, B-Cell
1
Interventions
pembrolizumab
74
Nivolumab
53
Ipilimumab
42
Cyclophosphamide
32
Interleukin-2
24
aldesleukin
23
Temozolomide
17
fludarabine
16
Biopsy
11
trametinib
10
fludarabine phosphate
10
dabrafenib
10
spartalizumab
8
Paclitaxel
8
Dacarbazine
8
sargramostim
7
cemiplimab
7
binimetinib
7
Cisplatin
7
Bevacizumab
7
poly ICLC
6
lenvatinib
6
epacadostat
6
Radiotherapy
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
montanide ISA 51
5
encorafenib
5
atezolizumab
5
Vemurafenib
5
Specimen Handling
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Melanoma
×
varlilumab
×
Clear all
NCT03617328
2024-02-06
Mel-65
University of Virginia
Phase 1/2
Completed
33 enrolled